Indivior Pharmaceuticals (INDV) Liabilities and Shareholders Equity (2023 - 2026)

Indivior Pharmaceuticals has reported Liabilities and Shareholders Equity for 4 years, with the latest figure at $1.2 billion in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 15.08% year-over-year to $1.2 billion in Q2 2026; TTM through Jun 2026 was $5.0 billion, a 21.82% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, down 8.74% from the prior year.
• Liabilities and Shareholders Equity was $1.2 billion for Q2 2026 at Indivior Pharmaceuticals, up from $1.2 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.8 billion in Q4 2023, with the low at $1.2 billion in Q1 2026.
• Average Liabilities and Shareholders Equity over 4 years is $1.4 billion, with a median of $1.3 billion recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity fell 25.14% in 2024, then retreated 8.74% in 2025.
• Over 4 years, Liabilities and Shareholders Equity stood at $1.8 billion in 2023, then decreased by 25.14% to $1.3 billion in 2024, then decreased by 8.74% to $1.2 billion in 2025, then rose by 2.66% to $1.2 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.2 billion (Q2 2026), $1.2 billion (Q1 2026), and $1.2 billion (Q4 2025), per Business Quant data.